Alan Wright1, Greg A. Fellows2, John R. Griffiths3, Martin Wilson4,5, B Anthony Bell2, Franklyn Arron Howe2
1Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 2St George's University of London, United Kingdom; 3CRUK Cambridge Research Institute, United Kingdom; 4University of Birmingham, United Kingdom; 5Birmingham Childrens Hospital NHS Foundation Trust, United Kingdom
MRS has the potential to provide diagnostic and prognostic biomarkers for brain tumours in vivo. We have used the ex vivo technique of 1H HRMAS NMR spectroscopy of brain tumour samples to identify the NMR visible metabolites in the common adult brain tumours. This has lead to the identification of 29 small molecule metabolites observable in spectra from a set of 65 tumours including grade II astrocytomas, grade III gliomas, GBMs, lymphomas, metastases and meningiomas. We have also identified some novel-potential biomarkers for binary brain-tumour diagnostic comparisons. These include hypotaurine as a marker for GBM when compared to metastases or histidine as a positive marker for gliomas when compared to metastases or meningioma.